全球抗疫英雄谱——奋战在国际抗击新冠肺炎（COVID-19）一线的医护人员
111

印第安纳大学新冠疫苗研究人员查迪·哈格（Chadi Hage）：战胜新冠病毒后，重返岗位领导疫苗研发

查迪·哈格（Chadi Hage）是美国印第安纳大学医学院临床医学研究人员。他在与新冠肺炎作斗争的过程中不幸被感染，治愈出院后，他领导着他的科研团队对新冠肺炎展开反击。

3月底，哈格博士就开始针对新冠病毒进行临床试验，但是研究过程并不顺利。哈格博士表示，“在研究期间，我们暴露在充斥着新冠病毒的环境下，而且新冠肺炎疫情暴发初期，许多人都没有戴口罩的意识，大部分医疗卫生机构也没有发布关于穿戴个人防护用品的规定。现在政策发生了改变，所以包括我们在内的医护人员都受到了保护，我非常感谢政府和国家在这方面为医护工作者提供的支持。”

哈格博士在开展研究工作不久后，被诊断出感染了新冠肺炎。他持续发烧11天，从一个房间走到另一个房间都会感到呼吸困难。他的妻子和女儿也不幸被感染。值得庆幸的是，他们都已经恢复了健康。

在感染新冠肺炎康复出院后，哈格博士立即组织印第安纳大学医学院研究人员，开展了两项有关新冠肺炎患者免疫系统、免疫反应的临床试验。他希望自己的研究成果能够给新冠肺炎患者带来帮助。“感染这种疾病会给你带来一些改变，你能够充分了解患者正在经历的痛苦，也会对他们的症状有进一步的认识，所以我们才会进行这些临床试验，希望为患者提供帮助。”他说。

哈格博士向现在仍然质疑新冠肺炎是否属实的人们发出警告：“新冠肺炎并不是谎言，这种病毒真的可以杀死你。有时候，人们在目睹周围人感染这种疾病后，才肯相信这种疾病是真实存在的。但是这种疾病非常危险，波及所有年龄段。”

哈格博士指出，在感染新冠病毒后，人们的免疫系统会对病毒产生反应，尝试控制这种病毒，然而这种免疫反应也可能会诱发其他疾病。他解释说：“新冠病毒会诱发全身炎症反应，给患者带来极大的危害。我们正在进行的两项临床试验，致力于解决这个问题。我们通过确定免疫反应的特定成分，化解这种炎症反应。”

哈格博士表示，这两项临床试验目前只对正在接受治疗的患者开放。两项临床试验原定于今年年底完成，也可能会根据申请参加的人数进行扩展。

IU doctor survives COVID-19, leads team of coronavirus researchers in clinical trials

A doctor’s personal fight against COVID-19 brought him to his knees. Now, he’s fighting back by leading a team of coronavirus researchers.

Dr. Chadi Hage began work on a couple COVID-19 clinical trials during the end of March. But the coronavirus had its own plans.

“It comes with the job. We get exposed. Early on we were not wearing masks all the time in the hospital. Thank God that policy changed, so now we’re all protected,” said Dr. Chadi Hage, who is an associate professor of clinical medicine at Indiana University School of Medicine.

Hage soon got sick, and was diagnosed with COVID-19.

“I’m relatively young, I’m very healthy, and that thing brought me to my knees,” he said.

He had a fever that lasted 11 days. Just walking from room to room was exhausting.

“Chills, I lost a lot of weight. Sweating, stomach symptoms were rough. Extremely rough. I was exhausted for weeks after the illness,” Hage said. “I couldn’t do anything.”

His wife, and his teenage daughter both wound up sick with COVID-19, too.

“The hardest part is to give it to your child. That’s the hardest part. But, thank God she did well, and they’re all recovered,” Hage said.

Hage now leads IU School of Medicine researchers in two clinical trials that deal with a patient’s immune system and its response to COVID-19.

He started this work as he recovered from the coronavirus, himself and he says his mission is to truly help people.

“Going through this illness only humbles you, and gives you a real appreciation of what patients go through. I can understand how sick they get. That’s why we’re doing these clinical trials, to help them,” Hage said.

He has a strong message for people who doubt COVID-19.

“It is not a hoax. It can kill you. It’s extremely severe. I hate to say this, but sometimes, people want to know somebody personally who had the illness, to believe that it exists. It does exist. It makes anybody sick.”

There are two clinical trials going on that focus on people’s immune response to the coronavirus.

With COVID-19, Hage said after people get infected, their immune system mounts a response to the virus to try to control it. It’s that immune reaction that could lead to other ailments.

“The inflammatory response to the infection itself is really what makes people very sick. Two of the clinical trials that we are leading here address that. So, we address the immune response to the virus, by targeting specific components of the immune response. Specific molecules that the inflammatory response in the body works through, to cause the injury,” Hage explained.

He said these clinical trials are open for people who are already in the hospital sick with COVID-19. They are not open to people who are not sick or are not in the hospital.

The clinical trials are slated to finish at the end of this year, but they could be extended based on how many people enroll to participate.

来源：Indianapolis News, Indiana University

温馨说明：本栏目中文内容由我会根据来源处内容整理并翻译。